BackgroundColitis was the third most common immune-related adverse effect in melanoma patients treated with immune-checkpoint inhibitor (ICI). With the limitation of real-world data in the UK population, this study was conducted in a UK hospital where a fresh colitis guidance was introduced to evaluate the overall grading (OG) to assess colitis severity and guide the treatment.AimsThis study aimed to investigate colitis severity by Common Terminology Criteria for Adverse Events (CTCAE) grade and overall grade at time of presentation. Colitis treatment and outcome were evaluated to compare the impact of these two categories.MethodsA single-center, retrospective observational study was performed in melanoma patient developing colitis symptoms.ResultsA total of 44 advanced melanoma patient with colitis symptoms were included. Median time to colitis onset was 67 days (range 4–890). Majority of patients developed G1/ G2 of CTCAE scale (70.4%) but moderate or severe overall grade (84.1%). There were 65.9% of patients treated with steroids, and 38.2% with infliximab and 4.5% with vedolizumab. The median time of colitis resolution was 28 days (range 0–282). Both treatment modality and time to resolution were associated with severity of colitis assessed by complete OG(p<0.0001) rather than CTCAE grading (p>0.05).ConclusionsThis study provided a comprehensive description about ICI-induced colitis management in a single center of the UK. The more completed OG was proposed to stratify colitis patient and guide the investigation and treatment decision at presenting time, replacing the old CTCAE grading.

中文翻译：

---

通过总体分级量表评估黑色素瘤患者免疫检查点抑制剂治疗引起的结肠炎

背景结肠炎是接受免疫检查点抑制剂（ICI）治疗的黑色素瘤患者中第三大常见的免疫相关不良反应。由于英国人群真实世界数据的限制，本研究在英国一家医院进行，引入了新鲜的结肠炎指南，对总体分级（OG）进行评估，以评估结肠炎的严重程度并指导治疗。 目的本研究旨在探讨结肠炎严重程度按不良事件通用术语标准 (CTCAE) 分级和就诊时的总体分级。对结肠炎的治疗和结果进行评估，以比较这两个类别的影响。方法对出现结肠炎症状的黑色素瘤患者进行单中心、回顾性观察研究。结果共纳入 44 例出现结肠炎症状的晚期黑色素瘤患者。结肠炎发病的中位时间为 67 天（范围 4-890）。大多数患者的 CTCAE 等级为 G1/G2（70.4%），但总体分级为中度或重度（84.1%）。 65.9% 的患者接受类固醇治疗，38.2% 的患者接受英夫利昔单抗治疗，4.5% 的患者接受维多珠单抗治疗。结肠炎消退的中位时间为 28 天（范围 0-282）。治疗方式和缓解时间均与通过完整 OG 评估的结肠炎严重程度相关 (p<0.0001)，而不是 CTCAE 分级 (p>0.05)。 结论 这项研究提供了关于 ICI 诱导的结肠炎在单一中心的管理的全面描述。英国。更完整的 OG 被提议对结肠炎患者进行分层，并指导目前的调查和治疗决策，取代旧的 CTCAE 分级。